Skip to main content
Caplight Logo









Nemea Therapeutics, Inc.

Nemea Therapeutics, Inc.

Private
Houston, TexasHealthcare & Life Scienceshttps://nemeatx.com

Last Round

Seed

Apr 1, 2026

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Nemea Therapeutics, Inc. is a biotechnology company developing oral small molecule inhibitors targeting mitochondrial RNA polymerase for the treatment of solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

drug discoverybiotechnologysmall-molecule inhibitorsoncologypreclinical developmentmitochondrial biologyPOLRMTmitochondrial RNA polymerasetherapeutic assetsmedicinal chemistrybiotech startupdrug pipelineearly-stage biotechlife sciences

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nemea Therapeutics, Inc. Comparables

Compare Nemea Therapeutics, Inc. with similar companies based on industry and business-model similarity.

Nemea Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Imel Biotherapeutics
77%
Talus Bio
77%
KyDo Therapeutics
75%

Nemea Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedApr 1, 2026
Pre SeedNov 1, 2025

Nemea Therapeutics, Inc. Investors

Notable investors and investment history

Nemea Therapeutics, Inc. investors
InvestorRounds
KHAN Technology Transfer Fund IIPre Seed
MATWINAccelerator
BCM VenturesPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2026

    $25M raised in Seed round.

  • Nov 1, 2025

    $2M raised from BCM Ventures and KHAN Technology Transfer Fund II.

Nemea Therapeutics, Inc. Filings

Explore SEC and related filing metadata, where available.

Nemea Therapeutics, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nemea Therapeutics, Inc.'s valuation, stock price, and market status.

Is Nemea Therapeutics, Inc. a public or private company?

Nemea Therapeutics, Inc. is a private company.

What is the current stock price of Nemea Therapeutics, Inc.?

Nemea Therapeutics, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Nemea Therapeutics, Inc. worth (valuation)?

Valuation information for Nemea Therapeutics, Inc. is not publicly available.

Can I buy Nemea Therapeutics, Inc. stock?

Nemea Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Nemea Therapeutics, Inc.'s last funding round?

Nemea Therapeutics, Inc.'s most recent funding round was Pre Seed on April 1, 2026.

Who are the main investors in Nemea Therapeutics, Inc.?

Key investors in Nemea Therapeutics, Inc. include BCM Ventures.

Will Nemea Therapeutics, Inc. IPO soon?

No public IPO plans have been announced for Nemea Therapeutics, Inc..

How can I track Nemea Therapeutics, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nemea Therapeutics, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHouston, Texas
Year FoundedN/A
Last FundingApr 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?